Correction: PARP-1 inhibitor modulate &#x03B2;-catenin signaling to enhance cisplatin sensitivity in cancer cervix

Minakshi Mann; Sachin Kumar; Shyam S. Chauhan; Neerja Bhatla; Sunesh Kumar; Sameer Bakhshi; Ritu Gupta; Ashok Sharma; Lalit Kumar

doi:10.18632/oncotarget.27101

Oncotarget

Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science.

Its scope is unique. The term "oncotarget" encompasses all molecules, pathways, cellular functions, cell types, and even tissues that can be viewed as targets relevant to cancer as well as other diseases. The term was introduced in the inaugural Editorial, Introducing Oncotarget.

As of January 1, 2022, Oncotarget has shifted to a continuous publishing model. Papers will now be published continuously within yearly volumes in their final and complete form and then quickly released to Pubmed.

Subscribe to receive alerts once a paper has been published by Oncotarget.

Learn about our FREE

Post-Publication Promotion Services

50% on all publication fees until the end of 2024.

Impact Journals, LLC is the publisher of Oncotarget: www.impactjournals.com.

Impact Journals is a member of the Wellcome Trust List of Compliant Publishers.

Impact Journals is a member of the Society for Scholarly Publishing.

On December 23, 2022, Oncotarget server experienced a DDoS attack. As a result, Oncotarget site was inaccessible for a few hours. Oncotarget team swiftly dealt with the situation and took it under control. This malicious action will be reported to the FBI.

Corrections:

Correction: PARP-1 inhibitor modulate β-catenin signaling to enhance cisplatin sensitivity in cancer cervix

PDF | How to cite

Oncotarget. 2019; 10:4802-4802. https://doi.org/10.18632/oncotarget.27101

Metrics: PDF 1496 views | ?

Minakshi Mann¹, Sachin Kumar¹, Shyam S. Chauhan², Neerja Bhatla³, Sunesh Kumar³, Sameer Bakhshi¹, Ritu Gupta⁴, Ashok Sharma² and Lalit Kumar¹

¹ Department of Medical Oncology, Dr. B.R.A. Institute Rotary Cancer Hospital, All India Institute of Medical Sciences, New Delhi, India
² Department of Biochemistry, All India Institute of Medical Sciences, New Delhi, India
³ Department of Obstetrics and Gynecology, All India Institute of Medical Sciences, New Delhi, India
⁴ Laboratory Oncology Unit, Dr. B.R.A. Institute Rotary Cancer Hospital, All India Institute of Medical Sciences, New Delhi, India

Published: July 30, 2019

This article has been corrected: Dr. Ashok Sharma has been named as co-corresponding author on this paper, and has been moved from third place to second-to-last author in the listing.

Original article: Oncotarget. 2019; 10:4262–4275. DOI: https://doi.org/10.18632/oncotarget.27008.

All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 27101

Publication Alerts

Post-Publication Promotion

Publication Discount

Corrections:

Correction: PARP-1 inhibitor modulate β-catenin signaling to enhance cisplatin sensitivity in cancer cervix